Great response to a smart alec trying to make a case against Albuferon. Frankly, there is no risk in switching the treatment options. When Pegasys was introduced in the market patients switched almost instantaneously from Pegintron to Pegasys. Given Pegasys and Albuferon have similar efficacy and safety profile the # of patients switching will likely switch only because of fewer # of treatments required which can be a major factor but is a personal choice. I give them a 30% market share in 3 mos from launch which could eventually rise to about 40%. Most of this will come at the cost of Pegintron. In 6-12 mos the market will be divided Pegasys 40, Albuferon 40 and Pegintron 20 (all within a +/- 5% range). Biggest loser if Albuferon is approved will be Merck.